Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Tetanus toxoid vaccine adsorbed** is a sterile, cloudy, whitish suspension used for intramuscular injection to provide active immunization against tetanus in individuals seven years and older[3][5]. The vaccine is manufactured by growing *Clostridium tetani* in a suitable medium and detoxifying the toxin with formaldehyde to produce tetanus toxoid, which is then adsorbed onto an aluminum salt adjuvant (such as aluminum phosphate or aluminum potassium sulfate)[1][3]. Upon administration, the vaccine stimulates the immune system to produce antibodies against the tetanus toxin, conferring protective immunity. Some products combined tetanus toxoid with diphtheria toxoid (e.g., Td ADSORBED, TDVAX, TENIVAC), but some are solely tetanus toxoid adsorbed preparations[1][3][4]. The vaccine does not provide protection against other diseases and is not effective for the treatment of established tetanus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tetanus toxoid vaccine adsorbed.